Kiryluk Lab

IgAN Progression Calculator

This risk score is based on the analysis of 619 biopsy-diagnosed Chinese patients with IgA nephropathy followed for an average of 41.3 months from the time of diagnosis. The calculator uses four baseline clinical variables assessed at the time of biopsy to predict the risk of progression to end stage kidney disease. For details, please see: Xie, et al.: Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score. PLoS One 2012;7(6):e38904

IgAN Genetic Risk Calculator

Use this calculator to determine an individual's risk of developing IgA nephropathy based on specific genetic markers. The risk score equation is based on the 15 SNPs associated with IgA nephropathy in the analysis of 20,612 individuals from 14 international case-control cohorts of European and Asian ancestry. The risk score is standardized using genotypes of 1,050 individuals from 52 worldwide populations included in the Human Genome Diversity Project (HGDP). For details, please see: Kiryluk, et al.: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014 Oct 12. doi: 10.1038/ng.3118.

MN Genetic Risk Calculator

This calculator is designed to assess the risk of membranous nephropathy in an individual presenting with nephrotic syndrome. The risk calculation is based on a genetic risk profile combined with a serologic test for anti-PLA2R antibody. The genetic risk score equations are derived from GWAS analysis of 12,820 individuals (3,782 primary MN and 9,038 controls), including 4,841 individuals of East Asian ancestry (1,632 cases and 3,209 controls) and 7,979 individuals of European ancestry (2,150 cases and 5,829 controls). The risk score is calculated separately for Europeans and East Asians and standard-normalized using genotypes of healthy ancestry-matched controls. The serologic test results refer to antibody levels as determined by the anti-PLA2R IgG ELISA (EUROIMMUN Medizinische Labordiagnostika AG). The cut-offs that define a positive test (i.e. high risk patient) have 99% specificity. For details, please see: Xie et al.Genetic Architecture of Membranous Nephropathy and Its Potential to Improve Non-invasive Diagnosis. Nature Communications 11, 1600 (2020).